基本信息
刘龙超 男 博导 中国科学院微生物研究所
电子邮件： liulongchao@im.ac.cn
通信地址： 北京市朝阳区北辰西路1号院3号
邮政编码： 100101
电子邮件： liulongchao@im.ac.cn
通信地址： 北京市朝阳区北辰西路1号院3号
邮政编码： 100101
招生信息
招生专业
100102-免疫学
招生方向
肿瘤免疫治疗，肿瘤免疫微环境解码
教育背景
2011-09--2016-07 中国科学院大学 理学博士
2007-09--2011-06 吉林大学 理学学士
2007-09--2011-06 吉林大学 理学学士
工作经历
工作简历
2023-01~现在, 中国科学院微生物研究所, 研究员
2017-02~2022-11,美国德州大学西南医学中心, 博士后
2017-02~2022-11,美国德州大学西南医学中心, 博士后
专利与奖励
专利成果
（ 1 ） 腺病毒疫苗Ad‑LIGHT‑HBsAg及其用于治疗慢性乙肝的用途, 发明专利, 2017, 第 2 作者, 专利号: CN106701825A
（ 2 ） PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途, 专利授权, 2017, 第 5 作者, 专利号: CN106421774A
（ 2 ） PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途, 专利授权, 2017, 第 5 作者, 专利号: CN106421774A
出版信息
发表论文
[1] Liu Longchao, Chen Jiahui. Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. MEDICAL REVIEW[J]. 2023, 第 1 作者 通讯作者 2(6): 555-569, https://doaj.org/article/1eca498531774a61adc219a2d8950221.
[2] Xue Wang, Longchao Liu, Tao Yue, Zhichen Sun, Joonbeom Bae, Kuo-Fu Tseng, Anli Zhang, Jian Qiao, Yang-Xin Fu. Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8 + T cells. SIGNAL TRANSDUCTION AND TARGETED THERAPY[J]. 2023, 第 2 作者 通讯作者 8(1): 1-3, http://dx.doi.org/10.1038/s41392-023-01463-y.
[3] Moore, Casey, Bae, Joonbeom, Liu, Longchao, Li, Huiyu, Fu, YangXin, Qiao, Jian. Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. JCI INSIGHT[J]. 2022, 第 3 作者7(17): http://dx.doi.org/10.1172/jci.insight.159479.
[4] Li, Huiyu, Liu, Zhida, Liu, Longchao, Zhang, Hongyi, Han, Chuanhui, Girard, Luc, Park, Hyunsil, Zhang, Anli, Dong, Chunbo, Ye, Jianfeng, Rayford, Austin, Peyton, Michael, Li, Xiaoguang, Avila, Kimberley, Cao, Xuezhi, Hu, Shuiqing, Alam, Md Maksudul, Akbay, Esra A, Solis, Luisa M, Behrens, Carmen, HernandezRuiz, Sharia, Lu, Wei, Wistuba, Ignacio, Heymach, John, V, Chisamore, Michael, Micklem, David, Gabra, Hani, Gausdal, Gro, Lorens, James B, Li, Bo, Fu, YangXin, Minna, John D, Brekken, Rolf A. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells. CELL REPORTS MEDICINE[J]. 2022, 第 3 作者3(3): http://dx.doi.org/10.1016/j.xcrm.2022.100554.
[5] Bae, Joonbeom, Liu, Longchao, Moore, Casey, Hsu, Eric, Zhang, Anli, Ren, Zhenhua, Sun, Zhichen, Wang, Xue, Zhu, Jiankun, Shen, Jiao, Qiao, Jian, Fu, YangXin. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8(+) T cells to overcome immunotherapy resistance in cancer. NATURE CELL BIOLOGY. 2022, 第 2 作者
[6] Liu, Longchao, Chen, Jiahui, Zhang, Hongyi, Ye, Jianfeng, Moore, Casey, Lu, Changzheng, Fang, Yan, Fu, YangXin, Li, Bo. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. NATURE CANCER[J]. 2022, 第 1 作者3(4): 437-+, http://dx.doi.org/10.1038/s43018-022-00352-7.
[7] Lu, Changzheng, Guan, Junhong, Lu, Steve, Jin, Qihuang, Rousseau, Benoit, Lu, Tianshi, Stephens, Dennis, Zhang, Hongyi, Zhu, Jiankun, Yang, Mingming, Ren, Zhenhua, Liang, Yong, Liu, Zhida, Han, Chuanhui, Liu, Longchao, Cao, Xuezhi, Zhang, Anli, Qiao, Jian, Batten, Kimberly, Chen, Mingyi, Castrillon, Diego H, Wang, Tao, Li, Bo, Diaz, Luis A, Jr, Li, GuoMin, Fu, YangXin. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. CANCER CELL[J]. 2021, 第 15 作者39(1): 96-+, http://dx.doi.org/10.1016/j.ccell.2020.11.006.
[8] Liu, Longchao, Chen, Jiahui, Bae, Joonbeom, Li, Huiyu, Sun, Zhichen, Moore, Casey, Hsu, Eric, Han, Chuanhui, Qiao, Jian, Fu, YangXin. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. NATURE BIOMEDICAL ENGINEERING[J]. 2021, 第 1 作者5(11): http://dx.doi.org/10.1038/s41551-021-00800-2.
[9] Han, Chuanhui, Godfrey, Victoria, Liu, Zhida, Han, Yanfei, Liu, Longchao, Peng, Hua, Weichselbaum, Ralph R, Zaki, Hasan, Fu, YangXin. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. SCIENCE IMMUNOLOGY[J]. 2021, 第 5 作者6(59): http://dx.doi.org/10.1126/sciimmunol.abc6998.
[10] Deng, Sisi, Sun, Zhichen, Qiao, Jian, Liang, Yong, Liu, Longchao, Dong, Chunbo, Shen, Aijun, Wang, Yang, Tang, Hong, Fu, YangXin, Peng, Hua. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1(int)Tim-3(-)CD8(+) T cells. JCI INSIGHT[J]. 2020, 第 5 作者5(7): https://www.webofscience.com/wos/woscc/full-record/WOS:000526097500006.
[11] Zhang, Hongyi, Liu, Longchao, Zhang, Jian, Chen, Jiahui, Ye, Jianfeng, Shukla, Sachet, Qiao, Jian, Zhan, Xiaowei, Chen, Hao, Wu, Catherine J, Fu, YangXin, Li, Bo. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. CLINICAL CANCER RESEARCH[J]. 2020, 第 2 作者26(6): 1359-1371, http://dx.doi.org/10.1158/1078-0432.CCR-19-3249.
[12] Liu, Zhida, Han, Chuanhui, Dong, Chunbo, Shen, Aijun, Hsu, Eric, Ren, Zhenhua, Lu, Changzheng, Liu, Longchao, Zhang, Anli, Timmerman, Casey, Pu, Yang, Wang, Yang, Chen, Mingyi, Qiao, Jian, Fu, YangXin. Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. SCIENCE IMMUNOLOGY[J]. 2019, 第 8 作者4(38): http://dx.doi.org/10.1126/sciimmunol.aav6473.
[13] Yang, Kaiting, Liang, Yong, Sun, Zhichen, Liu, Longchao, Liao, Jing, Xu, Hairong, Zhu, Mingzhao, Fu, YangXin, Peng, Hua. T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. SCIENTIFIC REPORTS[J]. 2018, 第 4 作者8(1): https://doaj.org/article/25c58b45ade94631877a8476447b07e0.
[14] Liu, Xiaojuan, Liu, Longchao, Ren, Zhenhua, Yang, Kaiting, Xu, Hairong, Luan, Yan, Fu, Kai, Guo, Jingya, Peng, Hua, Zhu, Mingzhao, Fu, YangXin. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. CELL REPORTS[J]. 2018, 第 2 作者24(8): 2101-2111, http://dx.doi.org/10.1016/j.celrep.2018.07.062.
[15] Bian, Yingjie, Zhang, Zheng, Sun, Zhichen, Zhao, Juanjuan, Zhu, Danming, Wang, Yang, Fu, Sherry, Guo, Jingya, Liu, Longchao, Su, Lishan, Wang, FuSheng, Fu, YangXin, Peng, Hua. Vaccines Targeting PreS1 Domain Overcome Immune Tolerance in Hepatitis B Virus Carrier Mice. HEPATOLOGY[J]. 2017, 第 9 作者66(4): 1067-1082, https://www.webofscience.com/wos/woscc/full-record/WOS:000411735900010.
[16] Zhu, Danming, Liu, Longchao, Yang, Dan, Fu, Sherry, Bian, Yingjie, Sun, Zhichen, He, Junming, Su, Lishan, Zhang, Liguo, Peng, Hua, Fu, YangXin. Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. JOURNAL OF IMMUNOLOGY[J]. 2016, 第 2 作者196(7): 3079-3087, http://dx.doi.org/10.4049/jimmunol.1502061.
[17] Yang, Dan, Liu, Longchao, Zhu, Danming, Peng, Hua, Su, Lishan, Fu, YangXin, Zhang, Liguo. A mouse model for HBV immunotolerance and immunotherapy. CELLULAR & MOLECULAR IMMUNOLOGY[J]. 2014, 第 2 作者11(1): 71-78, http://dx.doi.org/10.1038/cmi.2013.43.
[2] Xue Wang, Longchao Liu, Tao Yue, Zhichen Sun, Joonbeom Bae, Kuo-Fu Tseng, Anli Zhang, Jian Qiao, Yang-Xin Fu. Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8 + T cells. SIGNAL TRANSDUCTION AND TARGETED THERAPY[J]. 2023, 第 2 作者 通讯作者 8(1): 1-3, http://dx.doi.org/10.1038/s41392-023-01463-y.
[3] Moore, Casey, Bae, Joonbeom, Liu, Longchao, Li, Huiyu, Fu, YangXin, Qiao, Jian. Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. JCI INSIGHT[J]. 2022, 第 3 作者7(17): http://dx.doi.org/10.1172/jci.insight.159479.
[4] Li, Huiyu, Liu, Zhida, Liu, Longchao, Zhang, Hongyi, Han, Chuanhui, Girard, Luc, Park, Hyunsil, Zhang, Anli, Dong, Chunbo, Ye, Jianfeng, Rayford, Austin, Peyton, Michael, Li, Xiaoguang, Avila, Kimberley, Cao, Xuezhi, Hu, Shuiqing, Alam, Md Maksudul, Akbay, Esra A, Solis, Luisa M, Behrens, Carmen, HernandezRuiz, Sharia, Lu, Wei, Wistuba, Ignacio, Heymach, John, V, Chisamore, Michael, Micklem, David, Gabra, Hani, Gausdal, Gro, Lorens, James B, Li, Bo, Fu, YangXin, Minna, John D, Brekken, Rolf A. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells. CELL REPORTS MEDICINE[J]. 2022, 第 3 作者3(3): http://dx.doi.org/10.1016/j.xcrm.2022.100554.
[5] Bae, Joonbeom, Liu, Longchao, Moore, Casey, Hsu, Eric, Zhang, Anli, Ren, Zhenhua, Sun, Zhichen, Wang, Xue, Zhu, Jiankun, Shen, Jiao, Qiao, Jian, Fu, YangXin. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8(+) T cells to overcome immunotherapy resistance in cancer. NATURE CELL BIOLOGY. 2022, 第 2 作者
[6] Liu, Longchao, Chen, Jiahui, Zhang, Hongyi, Ye, Jianfeng, Moore, Casey, Lu, Changzheng, Fang, Yan, Fu, YangXin, Li, Bo. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. NATURE CANCER[J]. 2022, 第 1 作者3(4): 437-+, http://dx.doi.org/10.1038/s43018-022-00352-7.
[7] Lu, Changzheng, Guan, Junhong, Lu, Steve, Jin, Qihuang, Rousseau, Benoit, Lu, Tianshi, Stephens, Dennis, Zhang, Hongyi, Zhu, Jiankun, Yang, Mingming, Ren, Zhenhua, Liang, Yong, Liu, Zhida, Han, Chuanhui, Liu, Longchao, Cao, Xuezhi, Zhang, Anli, Qiao, Jian, Batten, Kimberly, Chen, Mingyi, Castrillon, Diego H, Wang, Tao, Li, Bo, Diaz, Luis A, Jr, Li, GuoMin, Fu, YangXin. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. CANCER CELL[J]. 2021, 第 15 作者39(1): 96-+, http://dx.doi.org/10.1016/j.ccell.2020.11.006.
[8] Liu, Longchao, Chen, Jiahui, Bae, Joonbeom, Li, Huiyu, Sun, Zhichen, Moore, Casey, Hsu, Eric, Han, Chuanhui, Qiao, Jian, Fu, YangXin. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. NATURE BIOMEDICAL ENGINEERING[J]. 2021, 第 1 作者5(11): http://dx.doi.org/10.1038/s41551-021-00800-2.
[9] Han, Chuanhui, Godfrey, Victoria, Liu, Zhida, Han, Yanfei, Liu, Longchao, Peng, Hua, Weichselbaum, Ralph R, Zaki, Hasan, Fu, YangXin. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. SCIENCE IMMUNOLOGY[J]. 2021, 第 5 作者6(59): http://dx.doi.org/10.1126/sciimmunol.abc6998.
[10] Deng, Sisi, Sun, Zhichen, Qiao, Jian, Liang, Yong, Liu, Longchao, Dong, Chunbo, Shen, Aijun, Wang, Yang, Tang, Hong, Fu, YangXin, Peng, Hua. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1(int)Tim-3(-)CD8(+) T cells. JCI INSIGHT[J]. 2020, 第 5 作者5(7): https://www.webofscience.com/wos/woscc/full-record/WOS:000526097500006.
[11] Zhang, Hongyi, Liu, Longchao, Zhang, Jian, Chen, Jiahui, Ye, Jianfeng, Shukla, Sachet, Qiao, Jian, Zhan, Xiaowei, Chen, Hao, Wu, Catherine J, Fu, YangXin, Li, Bo. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. CLINICAL CANCER RESEARCH[J]. 2020, 第 2 作者26(6): 1359-1371, http://dx.doi.org/10.1158/1078-0432.CCR-19-3249.
[12] Liu, Zhida, Han, Chuanhui, Dong, Chunbo, Shen, Aijun, Hsu, Eric, Ren, Zhenhua, Lu, Changzheng, Liu, Longchao, Zhang, Anli, Timmerman, Casey, Pu, Yang, Wang, Yang, Chen, Mingyi, Qiao, Jian, Fu, YangXin. Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. SCIENCE IMMUNOLOGY[J]. 2019, 第 8 作者4(38): http://dx.doi.org/10.1126/sciimmunol.aav6473.
[13] Yang, Kaiting, Liang, Yong, Sun, Zhichen, Liu, Longchao, Liao, Jing, Xu, Hairong, Zhu, Mingzhao, Fu, YangXin, Peng, Hua. T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. SCIENTIFIC REPORTS[J]. 2018, 第 4 作者8(1): https://doaj.org/article/25c58b45ade94631877a8476447b07e0.
[14] Liu, Xiaojuan, Liu, Longchao, Ren, Zhenhua, Yang, Kaiting, Xu, Hairong, Luan, Yan, Fu, Kai, Guo, Jingya, Peng, Hua, Zhu, Mingzhao, Fu, YangXin. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. CELL REPORTS[J]. 2018, 第 2 作者24(8): 2101-2111, http://dx.doi.org/10.1016/j.celrep.2018.07.062.
[15] Bian, Yingjie, Zhang, Zheng, Sun, Zhichen, Zhao, Juanjuan, Zhu, Danming, Wang, Yang, Fu, Sherry, Guo, Jingya, Liu, Longchao, Su, Lishan, Wang, FuSheng, Fu, YangXin, Peng, Hua. Vaccines Targeting PreS1 Domain Overcome Immune Tolerance in Hepatitis B Virus Carrier Mice. HEPATOLOGY[J]. 2017, 第 9 作者66(4): 1067-1082, https://www.webofscience.com/wos/woscc/full-record/WOS:000411735900010.
[16] Zhu, Danming, Liu, Longchao, Yang, Dan, Fu, Sherry, Bian, Yingjie, Sun, Zhichen, He, Junming, Su, Lishan, Zhang, Liguo, Peng, Hua, Fu, YangXin. Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. JOURNAL OF IMMUNOLOGY[J]. 2016, 第 2 作者196(7): 3079-3087, http://dx.doi.org/10.4049/jimmunol.1502061.
[17] Yang, Dan, Liu, Longchao, Zhu, Danming, Peng, Hua, Su, Lishan, Fu, YangXin, Zhang, Liguo. A mouse model for HBV immunotolerance and immunotherapy. CELLULAR & MOLECULAR IMMUNOLOGY[J]. 2014, 第 2 作者11(1): 71-78, http://dx.doi.org/10.1038/cmi.2013.43.
科研活动
科研项目
（ 1 ） 课题组启动经费, 负责人, 研究所自主部署, 2023-02--2029-02
（ 2 ） 靶向肿瘤内T细胞的双特异性抗体治疗策略研究, 负责人, 国家任务, 2024-01--2027-12
（ 3 ） 重要病毒关键突变位点功能分子机制研究, 负责人, 国家任务, 2023-12--2026-11
（ 4 ） 肿瘤免疫治疗的机理及策略研究, 负责人, 国家任务, 2023-12--2026-12
（ 2 ） 靶向肿瘤内T细胞的双特异性抗体治疗策略研究, 负责人, 国家任务, 2024-01--2027-12
（ 3 ） 重要病毒关键突变位点功能分子机制研究, 负责人, 国家任务, 2023-12--2026-11
（ 4 ） 肿瘤免疫治疗的机理及策略研究, 负责人, 国家任务, 2023-12--2026-12